Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?

Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.

Zacks Investment Research • May 29, 2026

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference

MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the William Blair 46th Annual Growth Stock Conference.

GlobeNewsWire • May 27, 2026

Baron Health Care Fund Q1 2026 Portfolio Activity

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Seeking Alpha • May 27, 2026

Does BillionToOne (BLLN) Have the Potential to Rally 37% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 37% in BillionToOne (BLLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • May 25, 2026

BillionToOne - Starting 2026 Strong

BillionToOne delivered 84% YoY Q1 sales growth, driven by prenatal and oncology clinical testing segments. BillionToOne raised full-year revenue guidance to $450–$465 million, reflecting strong demand, pricing, and volume momentum. GAAP operating profit reached $17.8 million, demonstrating operating leverage and margin expansion amid declining pricing pressure.

Seeking Alpha • May 20, 2026

Wall Street Analysts Predict a 25.63% Upside in BillionToOne (BLLN): Here's What You Should Know

The mean of analysts' price targets for BillionToOne (BLLN) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • May 8, 2026

BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance

MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the first quarter ended March 31, 2026 and raised guidance for full year 2026.

GlobeNewsWire • May 6, 2026

BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • May 7, 2026

BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics

A breakthrough in prenatal care, Unity Confirm enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne's Fetal Cell Capture™ Technology MENLO PARK, Calif., May 1, 2026 /PRNewswire/ -- For more than two decades, the ultimate quest for scientists and clinicians studying prenatal genetics was the capture of an intact fetal cell non-invasively so that its fetal DNA could be directly analyzed.

PRNewsWire • May 1, 2026

BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology

Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategy MENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology.

PRNewsWire • Apr 2, 2026